Description
Product details
RAPIGLINIDE VOG 1.0 Repaglinide (1mg), Voglibose (0.3mg) Introduction: Effective management of diabetes mellitus requires a multifaceted approach that targets various aspects of glucose regulation. Repaglinide and voglibose are two medications that offer unique mechanisms of action in controlling blood sugar levels. RAPIGLINIDE VOG 1.0 combines repaglinide (1mg) and voglibose (0.3mg) to provide comprehensive glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of RAPIGLINIDE VOG 1.0 in diabetes management. Understanding Repaglinide and Voglibose: Repaglinide is a rapid-acting insulin secretagogue that stimulates insulin release from pancreatic beta cells, particularly after meals, thereby lowering blood glucose levels. Voglibose, on the other hand, is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, leading to reduced postprandial glucose spikes. By targeting different pathways, repaglinide and voglibose complement each other to achieve optimal glycemic control. Key Features of RAPIGLINIDE VOG 1.0: RAPIGLINIDE VOG 1.0 is a fixed-dose combination tablet containing repaglinide (1mg) and voglibose (0.3mg). This standardized formulation offers the convenience of combining two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The combination of repaglinide and voglibose provides a synergistic effect, allowing for better control of both fasting and postprandial hyperglycemia. Efficacy in Glycemic Control: Clinical studies have demonstrated the efficacy of RAPIGLINIDE VOG 1.0 in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). The combination of repaglinide and voglibose has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the rapid onset of action of repaglinide and the sustained effect of voglibose contribute to better glycemic control throughout the day. Safety Profile: RAPIGLINIDE VOG 1.0 exhibits a favorable safety profile, with adverse effects typically mild to moderate in severity. Common side effects may include gastrointestinal symptoms such as abdominal discomfort, diarrhea, or flatulence, which are often transient and diminish with continued use. Both repaglinide and voglibose are generally well-tolerated medications, with a low risk of hypoglycemia when used alone or in combination. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/rapiglinide-vog-1-0-134237
